No replies to this topic

[valiantchong]

Chronic Myeloid Leukemia Clinical Trials

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

An Open Label, Time-To-Event Continuous Reassessment Method, Phase I/II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib (Gleevec) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) With Persistent Molecular Disease.   

Study ID: UMCC 2008.093; Secondary ID: HUM 24993; Source: University of Michigan Cancer Center

Summary:

Patients participating in this study will have a diagnosis of Chronic Myeloid Leukemia. This

      study will evaluate whether the addition of an investigational drug called RAD001 given

      together with Imatinib will better target leukemia stem cells, causing them to die. Stem

      cells are a small population of cells, existing primarily within the bone marrow, and are

      believed to be responsible for the ongoing risk of disease relapse.